GLP1R and Parkinson disease: In particular, GLP-1R agonists, which have been approved by the FDA for the treatment of T2DM, are recently emerging as promising therapeutic agents in PD, increasing the expectations for identifying new PD drugs that could possibly be neuroprotective or even halt or reverse disease progression.